Sandoz Group AG, the Swiss generic drugmaker, forecast an uplift in profit growth this year as demand for cheaper medicines surges worldwide.
The company, which was spun off from Novartis AG last year, expects to generate a core earnings before interest, taxes, depreciation and amortization margin of 20% in 2024, which is up slightly on the 18.1% it achieved last year. It also plans to maintain mid-single digit revenue growth in 2024.
Sandoz began life a standalone company on Switzerland’s stock exchange in October 2023. The company makes generic drugs and in recent years has been increasingly focusing on ...
